trending Market Intelligence /marketintelligence/en/news-insights/trending/tuIcMjywDQMiCCJA3k9smQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Protalix BioTherapeutics announces reverse stock split at 1-for-10 ratio

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Protalix BioTherapeutics announces reverse stock split at 1-for-10 ratio

Protalix BioTherapeutics Inc. announced a reverse stock split of its shares at a 1-for-10 ratio, effective Dec. 19.

The Israeli company hopes to regain compliance with the New York Stock Exchange's price listing requirements through the reverse split.

Protalix will reduce common authorized shares from 350 million to 120 million after the split and outstanding shares will decrease from 148.38 million to 14.84 million. The company intends to adjust issued notes and the per share exercise price of outstanding options in proportion to the split.

American Stock Transfer & Trust Co. is the transfer agent for the reverse stock split.

Protalix is a biopharmaceutical company that develops therapies for genetic diseases.